Abbott's Underlying Strength in Devices Softens Near-Term Turbulence in Nutrition and Diagnostics

Since 2013, Abbott has continued to improve the profitability of its four segments: nutritionals, devices, diagnostics, and established pharmaceuticals. Although the company has made progress over the last 10 years, it still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.